Effects of N-acyl-2-hydroxymethyl aziridines on in vitro proliferative responses of human lymphocytes stimulated by mitogenes

General Physiology and Biophysics

Volumn 25, Issue 3, 2006, Pages 277-287

  Baba, A F ^a   Medjahed, W ^a   Merzouk, H ^a   Mulengi, J Kajima ^a   Belleville, J ^b   Prost, Josiane ^b  

^a UNIVERSITY OF TLEMCEN   (Algeria)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Aziridines; Interleukins; Lymphocyte proliferation; Mitogens

Indexed keywords

2 HYDROXYMETHYL 1 (N PHTALOYLALANYL)AZIRIDINE; 2 HYDROXYMETHYL 1 (N PHTALOYLGLYCYL)AZIRIDINE; 2 HYDROXYMETHYL 1 (N PHTALOYLPHENYLALANYL)AZIRIDINE; AZIRIDINE DERIVATIVE; CONCANAVALIN A; INTERLEUKIN 2; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGENIC AGENT;

ARTICLE; B LYMPHOCYTE ACTIVATION; CELL VIABILITY; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN;

AZIRIDINES; B-LYMPHOCYTES; CELL PROLIFERATION; CONCANAVALIN A; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-2; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MITOGENS; T-LYMPHOCYTES;

EID: 33845266757     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Altman A., Coggeshall K. M., Mustelin T. (1990): Molecular events mediating T cell activation. Adv. Immunol. 48, 227-360
2. Bishop G. A., Hsing Y., Hostager B. S., Jalukar S. V., Ramirez L. M., Tomai M. A. (2000): Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J. Immunol. 165, 5552-5557
3. Brittenden J., Heys S. D., Ross J., Eremin O. (1996): Natural killer cells and cancer. Cancer 77, 1226-1243
4. Cantrell D. A. (1996): T-cell antigen receptor signal transduction pathways. Annu. Rev. Immunol. 14, 259-274
5. Cantrell D. A., Smith K. A. (1984): The interleukin 2 T-cell system: a new cell growth model. Science 224, 1312-1316
6. Di Francesco A.. M., Hargreaves R. H., Wallace T. W., Mayalarp S. P., Hazrati A., Hartley J. A., Butler J. (2000): The abnormal cytotoxicities of 2,5-diaziridinyl-1,4-benzoquinone-3-phenyl esters. Anticancer Drug Des. 15, 347-359
7. Gao Y., Tang W., Dai X., Gao H., Chen G., Ye J., Chan E., Koh H. L., Li X., Zhou S. (2005): Effects of water soluble ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. Blood 106, 4225-4235
8. Gerlier D., Thomasset N. (1986): Use of MTT colorimetric assay to measure cell activation. J. Immunol. Methods 94, 57-63
9. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. (1982): Lymphokine activated killer cell phenomenon: lusis of natural killer resistant fresh solid tumor cells by interleukin 2 activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823-1841
10. Hanessian S., Cantin L. D. (2000): The synthesis of enantiomerically pure disubstituted aziridines and N-alkoxy aziridines. Tetrahedron Lett. 41, 787-790
11. Kowalczyk-Bronisz S. H., Zabska R. (1986): Studies on the derivatives of aziridine. I. Synthesis and immunopharmacological analysis of amides of α-aziridinyl-β-/p-chlorobenzoyl/-propionic acid. Arch. Immunol. Ther. Exp. (Warsz.) 34, 333-350
12. 2+ current in human leukemic T-cells. Cell Regul. 1, 99-112
13. Marchini S., Damia G., Broggini M., Pennella G., Ripamonti M., Marsiglio A., Geroni C. (2001): 4-demothoxy-3′-deamino-3′-aziridinyl-4′- methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Cancer Res. 61, 1991-1995
14. Medjahed W., Tabet Zalta A., Kajima Mulengi J., Baba Ahmed F. Z., Merzouk H. (2004): The synthesis of N-acyl-2-hydroxymethyl aziridines of biological interest. Tetrahedron Lett. 45, 1211-1213
15. Melief C. J. (1992): Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58, 143-175
16. Mosmann T. (1983): Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63
17. Nonnecke B. J., Franklin S. T., Nissen D. J. (1991): Leucine and its catabolites alter mitogen-stimulated DNA synthesis by bovine lymphocytes. J. Nutr. 121, 1665-1672
18. Papaioannou N., Evans C. A., Blank J. T., Miller S. J. (2001): Enantioselective synthesis of a mitosane core assisted by diversity-based catalyst discovery. Org. Lett. 3, 2879-2882
19. Purasiri P., Mckechni A., Heys S. D., Eremin O. (1997): Modulation in vitro of human natural cytotoxicity, lymphocyte proliferative response to mitogens and cytokine production by essential fatty acids. Immunology 92, 166-172
20. Rieckmann P., D'Alessandro F., Nordan R. P., Fauci A. S., Kehrl J. H. (1991): IL-6 and tumor necrosis factor-α. Autocrine and paracrine cytokines involved in B cell function. J. Immunol. 146, 3462-3468
21. Remers W. A., Iyengar B. C. (1995): Antitumor antibiotics. In: Cancer Chemotherapeutic Agents (Ed W. O. Foye), pp. 584-592, American Chemical Society, Washington D.C.
22. Reynolds R. C. (1995): Aziridines. In: Cancer Chemotherapeutic Agents (Ed W. O. Foye), pp. 186-197, American Chemical Society, Washington D.C.
23. Schacterle G. R., Pollack R. L. (1973): Simplified method for the quantitative assay of small amounts of proteins in biological materials. Anal. Biochem. 51, 654-660
24. Schirmeister T. J. (1999): New peptidic cysteine protease inhibitors derived from the electrophilic α-amine-acid aziridine-2,3-dicarboxylic acid. J. Med. Chem. 42, 560-572
25. Siwicki A. K., Fuller J. C. Jr., Nissen S., Morand M., Pozet F., Vincent F., Kazun B. (2004): Effects of HMB (β-hydroxy-β-methylbutyrate) on in vitro proliferative responses of sheatfish (Silurus glanis) and catfish (Ictalurus melas) lymphocytes stimulated by mitogens. Acta Vet. (Brno) 73, 119-122
26. Siwicki A. K., Mizak B. (2001): In vitro influence of methisoprinol on lymphocyte proliferation in dogs. Bull. Vet. Inst. Pulawy 45, 227-233
27. Testerman T. L., Gester J. F. Imbertson L. M., Reiter R. L., Gibson S. J., Wagner T. L., Tomai M. A. (1995): Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukocyte Biol. 58, 365-370
28. Van Kampen K. R. (1997): Immunotherapy and cytokines. Semin. Vet. Med. Surg. (Small anim.) 12, 186-192
29. Vedejs E., Naidu B. N., Klapars A., Warner D. L., Li V. S., Na Y., Kohn H. (2003): Synthetic enantiopure aziridinomitosenes: preparation, reactivity, and DNA alkylation studies. J. Am. Chem. Soc. 125, 15796-15806
30. Wagner T. L., Ahonen C. L., Couture A. M., Gibson S. J., Miller R. L., Smith R. M., Reiter M. J., Vasilakos J. P., Tomai M. A. (1999): Modulation of Th1 and Th2 cytokine production with the immune response modifiers R-848 and imiquimod. Cell. Immunol. 191, 10-18
31. Weiss A., Shield R., Newton M., Manger B., Imboden J. (1987): Ligand-receptor interactions required for commitment to the activation of the interleukin-2 gene. J. Immunol. 137, 445-447
32. Zabska R., Kowalczyk-Bronisz S. H. (1987): Studies on the derivatives of aziridine. II. Synthesis and immunopharmacological analysis of substituted amides and anilides of α-aziridinyl-β- /p-chlorobenzoyl/ -propionic acid. Arch. Immunol. Ther. Exp. (Warsz.) 35, 681-691